FDA clears at-home subcutaneous induction for Skyrizi in Crohn’s disease
Federal prosecutors charge 15 in a Los Angeles health care fraud takedown, the FDA approves bepirovirsen (Hibsago) for chronic hepatitis B, and Skyrizi gains at-home subcutaneous induction for Crohn’s disease.
Justice Department charges 15 in $2 billion Los Angeles health care fraud takedown
The Justice Department charges 15 in a $2 billion Los Angeles health care fraud takedown, a personalized mRNA melanoma vaccine cuts recurrence risk by 42%, and the FDA approves bepirovirsen for hepatitis B.
FDA approves Hibsago, the first antisense drug for chronic hepatitis B
The FDA approves Hibsago, the first antisense drug for chronic hepatitis B, the Philips Lumify ultrasound correction becomes a Class I recall after four deaths, and a Maryland lab owner is convicted of Medicare fraud.